Janssen Prods patents expiration
1. Edurant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(5 months ago) | |
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 1 month ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(5 months ago) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive patients with hiv-1 rna less than or equal to 100,000 at the start of thearpy; In combination wi...
Dosage: TABLET;ORAL
EDURANT family patents
2. Olysio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(1 year, 7 months from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
Market Authorisation Date: 22 November, 2013
Treatment: Method of treating hepatitis c
Dosage: CAPSULE;ORAL
OLYSIO family patents
3. Prezcobix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(4 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(10 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase; Treatment of hiv infection in adults and pediatric patients weighing a...
Dosage: TABLET;ORAL
PREZCOBIX family patents
4. Prezista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(4 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(10 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 23 June, 2006
Treatment: NA
Dosage: TABLET;ORAL
PREZISTA family patents
5. Symtuza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(4 months from now) | |
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 6 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | JANSSEN PRODS | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 7 months ago) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(14 years from now) | |
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...
Dosage: TABLET;ORAL
SYMTUZA family patents
6. Yondelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(4 years from now) | |
|
US8895557 (Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
YONDELIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic